A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase III Study to Evaluate the Efficacy and Safety of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

• Able and willing to provide a written informed consent before the study, fully understand the study and be able to complete the study according to the protocol;

• Male and female, ≥18 years;

• Judged by the investigator, clinical diagnosis with cUTI or AP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics;

• Urine specimen with evidence of pyuria；

• Have urine culture specimen obtained within 48 hours prior to randomization;

• 48 hours before random, allowing a short course of antimicrobial drug treatment is less than 24 hours (random rate ≤25%)

• Women of childbearing potential must have a negative serum pregnancy test before first dose, must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of contraception, with no plan of birth, sperm/ovum donation from the time of signed ICF till 14 days after end of treatment.